Delivery Order SPE2DB20D3103-SPE2DB24FM5K7

Award Date 2/2/24
Potential Completion Date 2/5/24
Potential Value $3.3K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,812.70, is for the supply of Lyrica 75 mg capsules. The contract has an ultimate completion date of August 13, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,239.04, is for the delivery of Lyrica 75 mg capsules. The contract has an ultimate completion date of November 5, 2024 and is a firm fixed-price type. This contract is a child award under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,775.37 firm fixed-price delivery order is for the supply of Lyrica 100 mg capsules. The contract has an ultimate completion date of April 1, 2025 and was awarded on March 31, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive...
This federal contract award, valued at $1,221.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lyrica 75 mg capsules. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is February 6, 2025. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor, and there is no...
This federal contract award, valued at $1,778.47, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lyrica 100 mg capsules. The contract is a delivery order with a firm fixed price, and the ultimate completion date is March 26, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide a delivery order for Lyrica 100 mg capsules. The contract has a ceiling value of $2,115.80 and a period of performance through August 18, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical, valued at up to $999,999,999.00...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lyrica 75 mg capsules. The fixed-price contract has an ultimate completion date of July 30, 2024 and a ceiling value of $2,713.64. The award is not set aside for any specific business type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lyrica 150 mg capsules. The contract has a firm fixed price of $1,086.30 and a performance period ending on July 17, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,231.92 firm fixed-price delivery order contract is for the delivery of Lyrica 75 mg capsules. The contract has a period of performance through May 7, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) the DLA has with Cencora, Inc., valued at up to $999,999,999.00, which serves as the primary vehicle for the...
This is a $31,178.17 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of Lyrica 150 mg capsules to support federal healthcare programs and facilities. The order has a performance period ending on September 12, 2024. This award is part of a larger indefinite-delivery/indefinite-quantity (IDIQ) contract valued at up to $999,999,999 held by AmerisourceBergen...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB24FM5K7
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract, valued at $3,290.71, is for the delivery of Lyrica 75 mg capsules to support federal healthcare programs.

The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense and other federal agencies. The contract does not have a set-aside designation, indicating open competition.

Generated 5/14/25, 10:13 AM